Simcere And JW Pharmaceutical Announce Collaboration And License Agreement For Anti-Gout Drug Candidate URC-102 In China

Simcere Pharmaceutical Group and JW Pharmaceutical (KRX:001060, hereinafter called “JWP”) announced a collaboration and exclusive license agreement for anti-gout drug candidate URC-102 in China (including Chinese Hongkong & Macao)

According to the agreement, Simcere will be responsible for the clinical research, registration and commercialization of URC-102 in China. Under the terms of the agreement, JWP will receive upfront payment, milestones and sales royalties from commercialization in China.

“The incidence of gout is rising year on year in China, presenting a large clinical need,” said Dr. Peng Wang, SVP of Simcere. “JWP has an excellent research team and expertise in new molecular entity discovery & development, which will be matched with the extensive experience of Simcere in clinical development and commercialization of innovative products of rheumatic diseases. We are pleased to have the opportunity to collaborate with JWP and hope we will bring URC-102 to patients soon with our joint efforts.”

“Given its growth potential, China has been our primary target to build strategic partnerships. It is a tremendous pleasure to select Simcere as the partner for URC102, an outstanding company with strong capabilities of new drug development as well as marketing and sales,” said Dr. SY Lee, who is the Chief of Corporate Development Division at JWP. He also added that “we will seek further diversified opportunities for URC-102’s global expansion as the gout market is rapidly growing and there is high demand for safe and effective new drugs due to the recently reported safety issues of the conventional gout medicines.”– PR Newswire